bioRxiv (Cold Spring Harbor Laboratory)
March 24, 2026
Kenneth Shinozuka, Mattia Rosso, Anna Chaiken et al.
1 citation
A single dose of the atypical psychedelic ibogaine can be highly effective at treating PTSD in veterans up to twelve months later, according to an observational study of 30 veterans. Using a novel EEG analysis method, researchers found that ibogaine shifted high-beta (24 and 25 Hz) brain networks from frontal areas toward posterior regions, an effect seen both three to four days and one month after treatment. This posterior shift correlated with improvements in PTSD symptoms and was replicated in an independent dataset on ibogaine for opioid use disorder. Neural modeling suggested the shift reflects increased corticocortical, not corticothalamic, connectivity. The reconfiguration of high-beta networks may be a robust biomarker for ibogaine's therapeutic effects.
Research Square
June 17, 2026
Martijn Arns, Kenneth Shinozuka, Joseph Barsuglia
Ibogaine, a substance showing early promise for treating substance use disorders and PTSD in veterans, carries a risk of cardiac arrhythmia and death. A retrospective multisite study of 19,071 patients treated under safety guidelines at 11 international clinics found that all six deaths occurring within 72 hours were among patients treated for opioid use disorder (6 out of 10,382), with no deaths among 8,689 non-SUD patients. A systematic review of ibogaine-associated fatalities mirrored this pattern: 41 of 44 fatalities with known indication involved substance use disorder, predominantly opioid detoxification. The findings indicate that ibogaine-associated mortality is largely confined to opioid detoxification and rare in non-SUD indications.
Tyler Maxwell Moore, Kathryn Walker, Emma Tung et al.
preprint
Adding psychotherapy to ketamine treatment does not significantly improve depression or PTSD symptoms more than ketamine alone over 30 days. Both approaches produced substantial, rapid symptom improvement that stabilized after 11-15 days. The study analyzed 202 help-seeking individuals (60% female, mean age 41.3 years) who received either ketamine alone or ketamine plus psychotherapy across six sessions. No significant differences in symptom trajectories emerged between the groups, though exploratory analyses suggested younger females might benefit more from combined treatment and older males from ketamine alone. The findings indicate ketamine's effects may be robust enough that concurrent psychotherapy does not enhance short-term outcomes, but longer-term and demographic-specific effects require further study.